Odyssey Therapeutics initiated with buy rating and $27 target price
ODTX•UBS initiated coverage of Odyssey Therapeutics with a buy rating and a $27 target price.
Related News
UK given access to safety-test latest AI models, minister says
QQQ•
Gold eases on strong dollar, oil prices; US inflation data eyed
GLD•
Dauch Corporation announces financial leadership succession plan and executive realignment
DCH•
Nasdaq trade halt: volatility trading pause at 09:46 AM
GIXI•
Citi seeks rapid resolution of its US regulatory burdens
C•